ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.64
-0.20%
US Tech 100
18,329.60
0.56%
S&P 500
5,316.70
0.18%
US Dollar vs CAD
1.36929
0.01%
Bitcoin
68,242.68
-1.25%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. YS Biopharma Company Ltd (YS)

  7. YS Biopharma Company Ltd (YS) News

YS

YS Biopharma (YS)

YS Biopharma Company Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:YS
DateTimeSourceHeadlineSymbolCompany
05/21/20243:15PMPR Newswire (US)YS Biopharma Announces Results of Extraordinary General MeetingNASDAQ:YSYS Biopharma Company Ltd
05/07/20243:20PMPR Newswire (US)YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive OfficerNASDAQ:YSYS Biopharma Company Ltd
04/29/20247:00AMPR Newswire (US)YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleNASDAQ:YSYS Biopharma Company Ltd
04/19/20246:00AMPR Newswire (US)YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024NASDAQ:YSYS Biopharma Company Ltd
04/18/20247:00AMPR Newswire (US)YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus VaccineNASDAQ:YSYS Biopharma Company Ltd
04/16/20247:00AMPR Newswire (US)YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024NASDAQ:YSYS Biopharma Company Ltd
04/09/20247:00AMPR Newswire (US)YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies VaccineNASDAQ:YSYS Biopharma Company Ltd
04/03/20247:00AMPR Newswire (US)YS Biopharma Announces Full Repayment of US$40,000,000 Loan FacilityNASDAQ:YSYS Biopharma Company Ltd
03/05/20247:00AMPR Newswire (US)YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese SubsidiariesNASDAQ:YSYS Biopharma Company Ltd
02/22/20244:00PMPR Newswire (US)YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024NASDAQ:YSYS Biopharma Company Ltd
02/18/20243:30AMPR Newswire (US)/C O R R E C T I O N -- YS Biopharma Co., Ltd./NASDAQ:YSYS Biopharma Company Ltd
02/16/20247:20PMPR Newswire (US)YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the MeetingNASDAQ:YSYS Biopharma Company Ltd
02/14/20247:00AMPR Newswire (US)YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate GovernanceNASDAQ:YSYS Biopharma Company Ltd
02/14/20246:50AMPR Newswire (US)YS Biopharma Announces Appointment of New DirectorsNASDAQ:YSYS Biopharma Company Ltd
02/12/20247:50AMPR Newswire (US)YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd.NASDAQ:YSYS Biopharma Company Ltd
02/09/20245:30AMPR Newswire (US)YS Biopharma Announces US$40 Million Private Placement FinancingNASDAQ:YSYS Biopharma Company Ltd
02/08/20245:10PMPR Newswire (US)Shareholders of YS Biopharma Announce an Extraordinary General MeetingNASDAQ:YSYS Biopharma Company Ltd
01/22/20244:00PMPR Newswire (US)YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024NASDAQ:YSYS Biopharma Company Ltd
01/08/20247:00AMPR Newswire (US)YS Biopharma Announces Changes to its Board CommitteesNASDAQ:YSYS Biopharma Company Ltd
12/20/20233:30PMPR Newswire (US)YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General MeetingNASDAQ:YSYS Biopharma Company Ltd
12/20/20237:56AMPR Newswire (US)YS Biopharma Co., Ltd. to Hold Extraordinary General Meeting on December 28, 2023NASDAQ:YSYS Biopharma Company Ltd
11/14/20237:30AMPR Newswire (US)Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price TargetNASDAQ:YSYS Biopharma Company Ltd
10/31/20237:30AMPR Newswire (US)YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies VaccineNASDAQ:YSYS Biopharma Company Ltd
10/26/20237:30AMPR Newswire (US)YS Biopharma Announces Receipt of Nasdaq NoticeNASDAQ:YSYS Biopharma Company Ltd
09/26/20237:30AMPR Newswire (US)YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies VaccineNASDAQ:YSYS Biopharma Company Ltd
09/15/20237:30AMPR Newswire (US)YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus InfectionNASDAQ:YSYS Biopharma Company Ltd
09/05/20237:30AMPR Newswire (US)YS Biopharma to Participate in Participate in Citi's 18th Annual Biopharma ConferenceNASDAQ:YSYS Biopharma Company Ltd
08/24/20233:15PMPR Newswire (US)YS Biopharma Announces Purchase of Shares by Company OfficersNASDAQ:YSYS Biopharma Company Ltd
08/15/20234:00PMPR Newswire (US)YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024NASDAQ:YSYS Biopharma Company Ltd
07/26/20234:00PMPR Newswire (US)YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023NASDAQ:YSYS Biopharma Company Ltd
 Showing the most relevant articles for your search:NASDAQ:YS

Your Recent History

BIT
1DEQ
Deutsche EuroShop
EU
ICBCB
Industrial Commercial Ba...
BIT
P1Z091
NLBNPIT1Z091 20240620 4900
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved